ArticleJAC-antimicrobial resistance2026
Exploring the perspectives of antimicrobial stewardship pharmacists in England on the subscription model for antimicrobial drugs.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The National Institute for Health and Care Excellence (NICE) introduced the world's first 'subscription-type' antimicrobial payment model in the UK in 2022 for ceftazidime-avibactam and cefiderocol, decoupling reimbursement from usage to stimulate innovation. The model is being expanded to additional antimicrobials. We aimed to explore the views of lead antimicrobial stewardship (AMS) pharmacists, key model implementers and stakeholders, using a nationwide survey. Methods: An online survey was distributed to lead AMS pharmacists of NHS acute Trusts ( Results: Forty-three pharmacists (response rate 32.8%) participated. Most were familiar with the model (86.1%) and supported its principle (88.4%), believing it promotes stewardship and innovation. Strong support existed for model expansion to antifungals, antivirals and novel modalities such as phage therapy.Key priority pathogens for candidate drugs included carbapenem-resistant Conclusions: AMS pharmacists view the subscription model positively but highlight the need to refine product award criteria to reflect clinical implementation priorities. Their insights are critical to optimizing future delinked payment models and ensuring equitable access to novel antimicrobials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.